Citations

Clear

949 citation(s) found for "Li, Bryan".

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Kaffenberger, Benjamin H. , Lunning, Matthew A. , McGettigan, Suzanne , McPherson, Jordan P. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Weight, Ryan , Johnson-Chilla, Alyse, Zuccarino-Catania, Griselda, Engh, Anita M. , Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Kaffenberger, B , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Pennell, Nathan A , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 230-241

10.6004/jnccn.2020.0012 | PMID 32135517 Get It

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
Exercise intolerance in heart failure: The important role of pulmonary hypertension
Taylor, Bryan J. , Shapiro, Brian P. , Johnson, Bruce D. , Taylor, Bryan J

Mayo Clinic

Experimental Physiology | February 24, 2020 | Volume: 105 | Issue: 12 | Pages: 1997-2003

10.1113/ep088105 | PMID 32092200 Get It

New Findings What is the topic of this review?This review concerns the negative impact of pulmonary hypertension (PH) on the pulmonary haemodynamic and gas exchange responses to exercise, considering the mechanisms by which PH plays a role in exercise intolerance in heart failure (HF) patients. What advances does it highlight?The hallmark limited pulmonary vascular ‘reserve’ and impaired pulmonary gas exchange responses to exercise in HF are worsened by the development of PH; these are key determinants of exercise intolerance. Even HF patients who present with ‘normal’ pulmonary vascular function experience exercise‐induced PH, which plays a role in exercise intolerance. AbstractPatients with heart failure universally complain of exertional intolerance, but the underlying cause(s) of this intolerance may differ between patients with different disease phenotypes. Exercise introduces an impressive stress to the lungs, where elevations in venous return and cardiac output engender substantial increases in pulmonary blood volume and flow. Relative to healthy individuals, the pulmonary vascular reserve to accept this increase in pulmonary perfusion is compromised in heart failure, with a growing body of evidence suggesting that the development of pulmonary hypertension (PH), and in particular a precapillary component of PH, worsens the pulmonary haemodynamic response to exercise in these patients. Characterized by an exaggerated increase in pulmonary arterial pressure and an elevation in pulmonary vascular resistance, this dysfunctional pulmonary haemodynamic response plays a role in exercise intolerance, probably through an impairment of right ventricular function, underperfusion of the pulmonary circulation and a subsequent reduction in systemic blood flow and oxygen delivery. The hallmark abnormalities in ventilatory and pulmonary gas exchange that accompany heart failure, including a greater ventilatory equivalent for carbon dioxide, are also worsened by the development of PH. This raises the possibility that measures of exercise pulmonary gas exchange might help to ‘describe’ underlying PH in heart failure; however, several fundamental issues and questions need to be addressed before such gas exchange measures could truly be considered efficacious measures used to differentiate the type of PH and track the severity of PH in heart failure.exercise intolerance, heart failure, pulmonary gas exchange, pulmonary haemodynamics, pulmonary hypertension
Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis
Kim, Minsuk , Vogtmann, Emily , Ahlquist, David A. , Devens, Mary E., Taylor, William R. , White, Bryan A. , Hale, Vanessa L. , Sung, Jaeyun , Chia, Nicholas , Sung, Jaeyun , Kim, Minsuk , Kisiel, John B. , Taylor, William R., Chia, Nicholas , Sinha, Rashmi R. , Chen, Jun

Mayo Clinic

mBio | February 17, 2020 | Volume: 11 | Issue: 1 | Pages: No page available

10.1128/mbio.03186-19 | PMID 32071266 Get It

Colorectal adenomas are precursors of CRC. Recently, the gut microbiota, i.e., the collection of microbes residing in our gut, has been recognized as a key player in CRC development. There have been a number of gut microbiota profiling studies for colorectal adenoma and CRC; however, fewer studies have considered the gut metabolome, which serves as the chemical interface between the host and gut microbiota. Here, we conducted a gut metabolome profiling study of colorectal adenoma and CRC and analyzed the metabolomic profiles together with paired microbiota composition profiles. We found several chemical signatures of colorectal adenoma that were associated with some gut microbes and potentially indicative of future CRC. This study highlights potential early-driver metabolites in CRC pathogenesis and guides further targeted experiments and thus provides an important stepping stone toward developing better CRC prevention strategies.
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study.
Schneider, Bryan J. , Abushahin, Laith , Birdas, Thomas J. , Kesler, Kenneth A., Burney, Heather , Perkins, Susan M. , Jalal, Shadia I. , Mamdani, Hirva Mansurali , Kasi, Pashtoon Murtaza

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 404-404

10.1200/jco.2020.38.4_suppl.404 Get It

404 Background: Concurrent chemoradiation(CRT) followed by esophagectomy is a standard of care for locally advanced esophageal(LA-EAC) and GEJ adenocarcinoma. Approximately 50% of patients(pts) experience disease relapse within the 1st yr after treatment(tx) completion. No adjuvant tx has been shown to improve survival in these pts. Immune checkpoint inhibitors have activity in metastatic PD-L1 positive EAC. Preclinical studies have shown radiation +/- chemotherapy upregulate PD-1/PD-L1 pathway. Methods: We conducted a phase II trial evaluating safety and efficacy of durvalumab(durva) in pts with LA-EAC and GEJ adenocarcinoma who have residual disease in surgical specimen after neoadjuvant CRT and R0 resection. Pts received durva 1500mg IV every 4 weeks for up to 1yr. Results: 24 pts were enrolled from 4/2016-1/2018(median age: 60yrs (range, 43-70). 18 received carbo/paclitaxel and 6 received cis/5-FU concurrently with radiation. Staging at diagnosis: T2N0(n = 3, 12.5%), T2N2(n = 3, 12.5%),T3N0(n = 6, 25%), T3N1(n = 6, 25%), T3N2(n = 4, 17%), T3N3(n = 1, 4%), T3Nx(n = 1, 4%).19 pts(79%) had positive lymph nodes(LNs) at the time of surgery following CRT. 12 pts completed 1yr of tx, 12 came off tx because of relapse(6), AEs(5), and consent withdrawal(1). Most common AEs were fatigue(n = 8, 33.3%) and nausea(n = 6, 25%). 3pts (12.5%) developed grade 3 irAEs: pneumonitis(1), hepatitis(1), colitis(1). At median follow up of 21.9mo(range, 1.7-23.9mo), 11 pts have relapsed: 9 distant and 2 locoregional. Two of 3 pts with grade 3 irAEs are alive and disease free at 17 and 23 mo respectively. 1-yr RFS and OS were 79.2% and 95.5%, respectively. RFS at 26 mo was 20.6%. Overall mOS and mOS after relapse were 28.1mo(range, 22.9-28.1) and 11.1 mo(range, 0.1-11.3mo) respectively. The study was expanded to enroll 14 additional pts who are currently undergoing tx. Conclusions: Adjuvant durvalumab following trimodality therapy for LA-EAC and GEJ adenocarcinoma is safe with improvement in 1-yr RFS to 79.2% compared to historical rate of 50%. RFS was 20.6% at 26 months. Evaluation of predictive biomarkers of RFS with durva is underway. Clinical trial information: NCT02639065.
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)
Aschenbrenner, Andrew J. , James, Bryan D. , Wang, Guoqiao , Lim, Yen Ying , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Xiong, Chengjie , Perrin, Richard J. , Buckles, Virginia, Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , O’Connor, Antoinette , Graff‐Radford, Neill R. , Gräber, Susanne, Martins, Ralph N. , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Hassenstab, Jason , Network, Dominantly Inherited Alzheimer, Cruchaga, Carlos , O'Connor, Antoinette , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , McDade, Eric , Xiong, Chengjie , Allegri, Ricardo , Ghetti, Bernardino , Goldman, Jill , Karch, Celeste M. , Lee, Jae‐Hong , Schofield, Peter R. , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 219-228

10.1002/alz.12010 | PMID 31914221 Get It

AbstractIntroductionAlthough some members of families with autosomal dominant Alzheimer's disease mutations learn their mutation status, most do not. How knowledge of mutation status affects clinical disease progression is unknown. This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers.MethodsMutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined.ResultsMutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non‐carriers. Carriers who learned their status mid‐study had slightly higher levels of depression and lower cognitive scores.DiscussionKnowledge of mutation status does not affect rates of change on any measured outcome. Learning of status mid‐study may confer short‐term changes in cognitive functioning, or changes in cognition may influence the determination of mutation status.
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Trabulsi, Edouard J. , Rosenkrantz, Andrew B. , Verma, Sadhna , Margolis, Daniel , Froemming, Adam T. , Oto, Aytekin , Milowsky, Matthew I. , Schlemmer, Heinz-Peter, Eiber, Matthias , Padhani, Anwar R. , Jain, Suneil , Pinto, Peter, Keegan, Kirk A., Porter, Christopher R., Jani, Ashesh B. , Kamradt, Jeffrey M., Sholes, Westley, Vargas, H. Alberto, Froemming, Adam, Rumble, R. Bryan , Jadvar, Hossein , Hope, Thomas A. , Pomper, Martin G. , Türkbey, Barış , Purysko, Andrei Saraiva , Morris, Michael J. , Choyke, Peter L. , Oldan, Jorge Daniel , Fanti, Stefano , Coleman, Jonathan , Bauman, Glenn

Mayo Clinic

Journal of Clinical Oncology | January 15, 2020 | Volume: 38 | Issue: 17 | Pages: 1963-1996

10.1200/jco.19.02757 | PMID 31940221 Get It

PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
Haagsma, Juanita A. , James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Lucchesi, Lydia R , Sylte, Dillon O , Adebayo, Oladimeji , Ahmadi, Alireza , Aichour, Miloud Taki Eddine, Alahdab, Fares , Al‐Raddadi, Rajaa , Alsharif, Ubai , Altirkawi, Khalid A , Anjomshoa, Mina, Appiah, Seth Christopher Yaw , Aremu, Olatunde , Arora, Amit , Assadi, Reza , Awasthi, Ashish , Quintanilla, Beatriz Paulina Ayala , Balalla, Shivanthi , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Behzadifar, Meysam, Bennett, Derrick , Bhaumik, Soumyadeep , Bhutta, Zulfiqar A , Bijani, Ali , Borges, Guilherme , Borschmann, Rohan , Bose, Dipan, Bražinová, Alexandra, Campuzano, Julio César , Cárdenas, Rosario , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catalá-López, Ferrán , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Crowe, Christopher S. , Dalal, Koustuv , Leo, Diego De, Neve, Jan‐Walter De , Deribe, Kebede , Dessie, Getenet , deVeber, Gabrielle , Dharmaratne, Samath Dhamminda , Doan, Linh Phuong , Driscoll, Tim , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Endries, Aman Yesuf , Faro, André , Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Fischer, Florian , Franklin, Richard C. , Fukumoto, Takeshi , Gezae, Kebede Embaye , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haghparast‐Bidgoli, Hassan , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hassen, Hamid Yimam , Havmoeller, Rasmus, Henok, Andualem , Hı́jar, Martha, Hole, Michael K., Rad, Enayatollah Homaie , Hossain, Naznin , Hostiuc, Sorin , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahanmehr, Nader , Jakovljević, Mihajlo , Jha, Ravi Prakash , Shushtari, Zahra Jorjoran , Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kalani, Rizwan, Kasaeian, Amir , Kelbore, Abraham Getachew , Kengne, André Pascal , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khan, Ejaz Ahmad , Kiadaliri, Ali , Kim, Yun Jin , Kısa, Adnan , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kumar, Manasi , Lalloo, Ratilal , Lam, Hilton Y. , Lami, Faris , Leasher, Janet L , Li, Shanshan , Linn, Shai , Lunevičius, Raimundas , Machado, Flávia Ribeiro , Razek, Hassan Magdy Abd El , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Malekzadeh, Reza, Malik, Manzoor Ahmad , Manda, Ana-Laura, Massenburg, Benjamin B. , Maulik, Pallab K , Meheretu, Hailemariam Abiy Alemu , Mehndiratta, Man Mohan, Mendoza, Walter, Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Moazen, Babak , Mezerji, Naser Mohammad Gholi, Mohammadibakhsh, Roghayeh , Mohammed, Shafiu , Molokhia, Mariam , Monasta, Lorenzo , Mondello, Stefania , Montero-Zamora, Pablo A. , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Moschos, Marilita M. , Mousavi, Seyyed Meysam , Murthy, Srinivas , Musa, Kamarul Imran , Naik, Gurudatta , Nangia, Vinay, Nascimento, Bruno Ramos , Ndwandwe, Duduzile , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Long Hoang , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oladimeji, Olanrewaju , Olagunju, Andrew T , Olagunju, Tinuke O , Orpana, Heather , Otstavnov, Stanislav S , Mahesh, P A , Pakhalé, Smita , Park, Eun‐Kee , Pesudovs, Konrad , Polinder, Suzanne , Prakash, Swayam , Rafay, Anwar, Rafiei, Alireza , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Kumar, Rajesh , Ramezanzadeh, Kiana, Rawaf, David Laith , Renzaho, André M. N. , Resnikoff, Serge , Roever, Leonardo , Sabde, Yogesh , Saddik, Basema , Salamati, Payman , Salimi, Yahya , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Satpathy, Maheswar , Sawhney, Monika, Sawyer, Susan M. , Şaylan, Mete , Schwebel, David C. , Seedat, Soraya , Shaikh, Masood Ali, Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sheikh, Aziz , Shigematsu, Mika, Shiri, Rahman , Shiue, Ivy , Silva, João Pedro , Sinha, Dhirendra Narain , Filho, Adauto Martins Soares , Soriano, Joan B. , Soshnikov, Sergey , Soyiri, Ireneous N , Starodubov, Vladimir I., Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Sunshine, Jacob E. , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Tessema, Gizachew Assefa , Thakur, Jarnail Singh , Car, Lorainne Tudor , Uzochukwu, Benjamin, Valdéz, Pascual , Varavikova, Elena A. , Vasconcelos, Ana Maria Nogales , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wijeratne, Tissa , Yadav, Priyanka , Yano, Yuichiro , Yenesew, Muluken Azage, Yisma, Engida , Younis, Mustafa Z , Zafar, Shamsa , Zaman, Sojib Bin , Zodpey, Sanjay , Hay, Simon I , Mokdad, Ali H. , Vos, Theo , Khubchandani, Jagdish , Padrón‐Monedero, Alicia , Wijeratne, T , Stein, Dan J , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Liu, Zichen, Roberts, Nicholas L S , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Aljunid, Syed Mohamed , Antonio, Carl Abelardo T. , Asayesh, Hamid , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Behzadifar, Meysam, Benjet, Corina L. , Benseñor, Isabela M. , Boufous, Soufiane , Carrero, Juan Jesús , Daryani, Ahmad , Daviţoiu, Dragoş Virgil , Degenhardt, Louisa J , Dolan, Kate A , Dubey, Manisha , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Filip, Irina , Gill, Tiffany K. , Gupta, Rahul, Hamidi, Samer , Haro, Josep María , Hassankhani, Hadi , Hendrie, Delia V. , Hı́jar, Martha , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Jonas, Jost B , Kabir, Ali , Kalani, Rizwan, Khoja, Abdullah T , Kim, Young‐Eun , Kim, Daniel , Koyanagi, Ai , Lansingh, Van Charles , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Melese, Addisu Dagnaw , Meštrović, Tomislav , Moradi‐Lakeh, Maziar , Morrison, Shane D. , Najafi, Farid , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Olivares, Pedro Rufino , Patton, George , Phillips, Michael , Radfar, Amir , Rawaf, Salman , Rezaeian, Shahab , Ronfani, Luca , Roshandel, Gholamreza , Saxena, Sonia , Schneider, Ione Jayce Ceola , Sepanlou, Sadaf Ghajarieh , Shen, Jiabin , Singh, Jasvinder A. , Стародубов, В. И. , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tran, Khanh Bao , Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Winkler, Andrea Sylvia , Azage, Muluken , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zhao, Yong , Lopez, Alan D , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | January 9, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i12-i26

10.1136/injuryprev-2019-043296 | PMID 31915273 Get It

Background The epidemiological transition of non-communicable diseases replacing infectious diseases as the main contributors to disease burden has been well documented in global health literature. Less focus, however, has been given to the relationship between sociodemographic changes and injury. The aim of this study was to examine the association between disability-adjusted life years (DALYs) from injury for 195 countries and territories at different levels along the development spectrum between 1990 and 2017 based on the Global Burden of Disease (GBD) 2017 estimates. Methods Injury mortality was estimated using the GBD mortality database, corrections for garbage coding and CODEm—the cause of death ensemble modelling tool. Morbidity estimation was based on surveys and inpatient and outpatient data sets for 30 cause-of-injury with 47 nature-of-injury categories each. The Socio-demographic Index (SDI) is a composite indicator that includes lagged income per capita, average educational attainment over age 15 years and total fertility rate. Results For many causes of injury, age-standardised DALY rates declined with increasing SDI, although road injury, interpersonal violence and self-harm did not follow this pattern. Particularly for self-harm opposing patterns were observed in regions with similar SDI levels. For road injuries, this effect was less pronounced. Conclusions The overall global pattern is that of declining injury burden with increasing SDI. However, not all injuries follow this pattern, which suggests multiple underlying mechanisms influencing injury DALYs. There is a need for a detailed understanding of these patterns to help to inform national and global efforts to address injury-related health outcomes across the development spectrum.
Deep brain stimulation for orthostatic tremor
Hewitt, Angela , Klassen, Bryan T. , Lee, Kendall H. , Hassan, Anhar , Hewitt, Angela L, Hewitt, Angela L , Gompel, Jamie J. Van

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 4 | Pages: 324-332

10.1212/cpj.0000000000000730 | PMID 32983612 Get It

SPECC1L regulates palate development downstream of IRF6
Hall, Everett G. , Wenger, Luke W., Wilson, Nathan R. , Undurty-Akella, Sraavya S, Standley, Jennifer , Augustine-Akpan, Eno-Abasi, Kousa, Youssef A. , Acevedo, Diana S., Goering, Jeremy P., Pitstick, Lenore, Natsume, Nagato , Paroya, Shahnawaz, Busch, Tamara , Mori, Akihiro , Schultz‐Rogers, Laura , Klee, Eric W. , Babovic‐Vuksanovic, Dusica , Kroc, Sarah A., Eshete, Mekonen , Bjork, Bryan C. , Suzuki, Satoshi , Murray, Jeffrey C. , Schutte, Brian C. , Butali, Azeez , Saadi, Irfan , Schultz-Rogers, Laura E, Babovic-Vuksanovic, Dusica, Wilson, Nathan R, Augustine‐Akpan, Eno‐Abasi, Ito, Masaaki, Mori, Akihiro, Imura, Hideto , Adeyemo, Wasiu Lanre

Mayo Clinic

Human Molecular Genetics | January 6, 2020 | Volume: 29 | Issue: 5 | Pages: 845-858

10.1093/hmg/ddaa002 | PMID 31943082 Get It

Abstract SPECC1L mutations have been identified in patients with rare atypical orofacial clefts and with syndromic cleft lip and/or palate (CL/P). These mutations cluster in the second coiled-coil and calponin homology domains of SPECC1L and severely affect the ability of SPECC1L to associate with microtubules. We previously showed that gene-trap knockout of Specc1l in mouse results in early embryonic lethality. We now present a truncation mutant mouse allele, Specc1lΔC510, that results in perinatal lethality. Specc1lΔC510/ΔC510 homozygotes showed abnormal palate rugae but did not show cleft palate. However, when crossed with a gene-trap allele, Specc1lcGT/ΔC510 compound heterozygotes showed a palate elevation delay with incompletely penetrant cleft palate. Specc1lcGT/ΔC510 embryos exhibit transient oral epithelial adhesions at E13.5, which may delay shelf elevation. Consistent with oral adhesions, we show periderm layer abnormalities, including ectopic apical expression of adherens junction markers, similar to Irf6 hypomorphic mutants and Arhgap29 heterozygotes. Indeed, SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves. Finally, we wanted to determine if SPECC1L deficiency also contributed to non-syndromic (ns) CL/P. We sequenced 62 Caucasian, 89 Filipino, 90 Ethiopian, 90 Nigerian and 95 Japanese patients with nsCL/P and identified three rare coding variants (p.Ala86Thr, p.Met91Iso and p.Arg546Gln) in six individuals. These variants reside outside of SPECC1L coiled-coil domains and result in milder functional defects than variants associated with syndromic clefting. Together, our data indicate that palate elevation is sensitive to deficiency of SPECC1L dosage and function and that SPECC1L cytoskeletal protein functions downstream of IRF6 in palatogenesis.
A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines
Sawka, Anna M. , Gagliardi, Anna R. , Haymart, Megan R. , Bernet, Victor , Hoff, Kelly, Brito, Juan P. , Haugen, Bryan R. , Kim, Brian W. , Kopp, Peter , Mandel, Susan J., Ross, Douglas S. , Sarne, David , Sinclair, Catherine F. , Jonklaas, Jacqueline , Brito, Juan P , Sturgeon, Cord , Angelos, Peter , Samuels, Mary H. , Sarne, David

Mayo Clinic

Thyroid® | December 13, 2019 | Volume: 30 | Issue: 1 | Pages: 25-33

10.1089/thy.2019.0486 | PMID 31830853 Get It

Background: The 2015 American Thyroid Association (ATA) clinical practice guidelines (CPGs) on management of thyroid nodules (TNs) and differentiated thyroid cancer (DTC) in adults were developed to inform clinicians, patients, researchers, and health policy makers about the best available evidence, and its limitations, relating to management of these conditions. Methods: We conducted a cross-sectional electronic survey of ATA members' perspectives of these CPGs, using a standardized survey (Clinician Guidelines Determinant Questionnaire) developed by the Guidelines International Network. A survey link was electronically mailed to members in February of 2019, with reminders sent to nonrespondents 2 and 5 weeks later. Data were descriptively summarized, after excluding missing responses. Results: The overall response rate was 19.8% (348/1761). The effective response rate was 20.2% (348/1720), after excluding a recently deceased member and individuals who had either invalid e-mail addresses or whose e-mails were returned. Of the respondents, 37.9% (132/348) were female, 60.4% (209/346) were endocrinologists, 27.5% (95/346) were surgeons, and 3.5% (12/346) were nuclear medicine specialists. The majority of respondents (71.9%; 250/348) were at a mid- or advanced-career level, and more than half were in academia (57.5%; 195/339). The majority (69.8%; 243/348) practiced in North America. The vast majority of respondents indicated that the CPGs explained the underlying evidence (92.3%; 298/323) and 92.9% (300/323) agreed or strongly agreed with the content. Most respondents stated that they regularly used the CPGs in their practice (83.0%; 268/323). Most respondents (83.0%; 268/323) also agreed or strongly agreed that the recommendations were easy to incorporate in their practice. The most popular CPG format was an electronic desktop file (78.8%; 252/320). Shorter more frequent CPGs were favored by 55.0% (176/320) of respondents, and longer traditional CPGs were favored by 39.7% (127/320). Conclusions: The clinical content and evidence explanations in the adult TN and DTC CPGs are widely accepted and applied among ATA survey respondents. Future ATA CPG updates need to be optimized to best meet users' preferences regarding format, frequency, and length.